Release Date: February 07, 2025 07:00AM Eastern Standard Time
Light AI Announces Engagement with Regulatory Partner Emergo by UL for Global Regulatory Submissions
VANCOUVER, BC, Feb. 7, 2025 /CNW/ – Light AI Inc. (“Light AI” or the “Company”) (CBOE CA: ALGO) (FSE: OHCN) a global healthcare technology company focused on developing artificial intelligence health diagnostic and wellness applications, today announced its partnership with Emergo by UL , a leading consulting firm specializing in global regulatory compliance and human factors for products in the medical industry. This collaboration marks a significant step forward in Light AI’s mission to achieve commercial success in multiple international markets.
Emergo by UL will support Light AI in navigating the complex landscape of regulatory submissions,
starting with immediate development efforts for Health Canada. Beyond this initial focus, Emergo will
play a crucial role in shaping Light AI’s comprehensive global strategy for regulatory compliance. Peter Whitehead, CEO of Light AI, expressed his enthusiasm for the partnership: “I am excited to have a talented group such as Emergo by UL support our submission development for Health Canada. They will also support in developing our global strategy of regulatory submissions. Emergo by UL’s extensive experience and proven track record in the medical industry make them an invaluable partner as Light AI continues to expand its reach and impact across various international markets.”
About Light AI Inc. (CBOE CA: ALGO / FSE: OHCN)
Light AI Inc. is a healthcare company focused on developing artificial intelligence health diagnostic applications. Light AI is developing a technology platform which represents the next generation of
patient management: it applies AI algorithms to smartphone images—starting with images of StrepA—to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind—its hardware platform is the 4.5B smartphones that exist in the world today.
In pre-FDA validation studies, Light AI’s algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (GAS). The Company’s algorithm generated pre-Federal Drug Administration (FDA) results were in the range of the “Gold Standard” swab culture currently used for diagnosing GAS achieving a 96.57% accuracy rate that is and a Negative Predictive Value (NPV) of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide.
If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (RHD), which imposes a global economic burden exceeding $1 trillion annually. Light AI’s technology offers a significant advancement in the accurate and timely diagnosis of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI’s approach to applying AI to
smartphone images can be expanded to other throat conditions, as well as other areas of analysis, such as the human eye and skin. Light AI’s vision is to combine the smartphone with AI in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes
ON BEHALF OF THE COMPANY
George Reznik
Chief Financial Officer
